Co-Authors
This is a "connection" page, showing publications co-authored by Mitchell C. Posner and Kevin K. Roggin.
Connection Strength
2.601
-
Modern treatment of gastric gastrointestinal stromal tumors. World J Gastroenterol. 2012 Dec 14; 18(46):6720-8.
Score: 0.456
-
Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait? Lancet Oncol. 2010 May; 11(5):404-5.
Score: 0.379
-
What is the long-term safety and efficacy of laparoscopic resection for gastric gastrointestinal stromal tumors? Nat Clin Pract Gastroenterol Hepatol. 2007 Feb; 4(2):76-7.
Score: 0.303
-
D3 or not D3... that is not the question. Lancet Oncol. 2006 Apr; 7(4):279-80.
Score: 0.286
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.187
-
Implementing a resident acute care surgery service: Improving resident education and patient care. Surgery. 2017 03; 161(3):876-883.
Score: 0.150
-
Prospective clinical trial of diagnostic peritoneal lavage to detect positive peritoneal cytology in patients with gastric cancer. J Surg Oncol. 2013 Jun; 107(8):794-8.
Score: 0.116
-
Predictors of unsuccessful laparoscopic resection of gastric submucosal neoplasms. J Gastrointest Surg. 2013 Feb; 17(2):244-55; discussion 255-6.
Score: 0.114
-
Preemptive surgery for premalignant foregut lesions. J Gastrointest Surg. 2009 Oct; 13(10):1874-87.
Score: 0.089
-
A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg. 2007 Jun; 11(6):758-66.
Score: 0.078
-
ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Dec; 29(Suppl 3):616-617.
Score: 0.057
-
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05.
Score: 0.053
-
Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Ann Surg Oncol. 2021 Aug; 28(8):4433-4443.
Score: 0.050
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.049
-
Virtual Surgical Fellowship Recruitment During COVID-19 and Its Implications for Resident/Fellow Recruitment in the Future. Ann Surg Oncol. 2020 Dec; 27(Suppl 3):911-915.
Score: 0.048
-
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
Score: 0.040
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.040
-
Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg. 2014 May; 259(5):960-5.
Score: 0.031
-
Implementing an excellence in teaching recognition system: needs analysis and recommendations. J Surg Educ. 2013 Nov-Dec; 70(6):731-8.
Score: 0.030
-
Continuous, data-rich appraisal of surgical trainees' operative abilities: a novel approach for measuring performance and providing feedback. J Surg Educ. 2009 Sep-Oct; 66(5):255-63.
Score: 0.023
-
Use of a novel, web-based educational platform facilitates intraoperative training in a surgical oncology fellowship program. Ann Surg Oncol. 2009 May; 16(5):1100-7.
Score: 0.022